Innovative silicon-based DNA synthesis from Twist Bioscience, a synthetic biology company.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its sili Twist Bioscience Announces Pricing … New Leads for COVID-19 Therapeutics and DiagnosticsTwist has proven itself to be a true next-generation DNA synthesis supplier, with the capacity to rapidly provide 1000s of genes at a price keenly awaited by the user community for many years.The sequences we designed were very difficult to work with, and the only way we could have completed this project was to have them synthesized and cloned by Twist Bioscience.The quality of Twist's oligo pools and the rapid turnaround time of the oligo synthesis helped us accelerate our understanding of the pseudouridine landscape on mammalian RNA. This press release contains forward-looking statements. Twist intends to use the net proceeds of the offering, along with its existing cash, cash equivalents and short-term investments to scale investment in its research and development organization, which includes investing in pharmaceutical biologics drug discovery and in DNA data storage, to increase its investment in its commercial organization to support the growth of its NGS, synbio, pharmaceutical biologics drug discovery (antibody) programs and its global expansion, to scale its NGS, synbio and pharmaceutical biologics drug (antibody) discovery operations and to expand its production capacity, which may require it to add an additional manufacturing location, and for the remainder to fund working capital and general corporate purposes.
Twist Bioscience Corporation Announces Pricing of Initial Public Offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation, or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. October 31, 2018 02:45 PM Eastern Daylight Time. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. 3, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 3,030,303 shares of its common stock at a price to the public of $33.00 per share. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. Twist may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 3,030,303 shares of its common stock at a price to the public of $33.00 per share. The securities described above are being offered by Twist pursuant to an automatic shelf registration statement on Form S-3 that was filed with the SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#DNA–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 3,030,303 shares of its common stock at a price to the public of $33.00 per share. Such risks and uncertainties include, among others, the risks and uncertainties set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Twist Bioscience Announces Pricing of a $100 Million Public Offering of Common Stock SAN FRANCISCO--(BUSINESS WIRE)--Feb. 19, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 4,642,857 shares of its common stock at a price to the public of $28.00 per share. All statements other than statements of historical facts contained herein, including without limitation statements regarding expected net proceeds from the offering, expected use of proceeds, and the timing of the closing of the offering, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Twist Bioscience makes high-quality gene synthesis, oligo pools, exome, NGS target enrichment, variant libraries and other synthetic DNA tools.